康希诺生物股份公司

Chinese vaccine company founded in January 2009 in the Tianjin Economic-Technological Development Area by a group of returnee scientists from international vaccine companies, listed on the Hong Kong Stock Exchange under code 6185 since March 2019 and on the Shanghai STAR Market under code 688185 since August 2020. Develops, manufactures and commercialises human vaccines using adenovirus vector, protein and conjugation platforms, with marketed products including the Convidecia adenovirus vectored COVID-19 vaccine, the Ad5-EBOV Ebola vaccine and quadrivalent and bivalent meningococcal conjugate vaccines, and a pipeline covering pertussis, pneumococcal and tuberculosis vaccines.